Skip to main content
Sarcoma logoLink to Sarcoma
. 1997 Mar;1(1):31–38. doi: 10.1080/13577149778452

The Impact of Radiotherapy Dose on Local Control of Ewing's Sarcoma of Bone

Neil G Burnet 1,3,, Judith M Bliss 2, Clive L Harmer 1
PMCID: PMC2373576  PMID: 18521198

Abstract

Purpose. Improvements in the systemic management of Ewing's sarcoma of bone over the last 20 years have led to a dramatic improvement in survival. The corollary is that treatment of the primary disease requires re-evaluation, since a significant number of patients still suffer local relapse.

Patients. The effect of radiation dose on local control was reviewed in a series of 96 patients treated between 1967 and 1986. Seventy-four had no metastases at presentation (M0), 22 had metastases (M1). The 5-year survival of all patients was 28%, and of M0 patients alone 37%. Although these figures are poor by today's standards, they are consistent with published studies whose patients were enrolled during the same calendar period. Although most deaths occurred by 5 years, survival continued to fall beyond 10 years, which has implications for follow-up in future studies.

Results. The local control (LC) rate at 5 years was 56% for all patients and for M0 patients analyzed separately. There was no difference in either LC or survival between the first and second decades of the study. Primary site was a significant determinant of survival and local control, with better outcome for limb tumours compared to pelvic primaries. Chemotherapy also had a major effect on LC. Radiotherapy improved the probability of LC. Omission of radiotherapy, or a dose <40 Gy, was ineffective. In the dose range 40–66 Gy, there was no evidence of a dose–response relationship.

Full Text

The Full Text of this article is available as a PDF (194.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbieri E., Emiliani E., Zini G., Mancini A., Toni A., Frezza G., Neri S., Putti C., Babini L. Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1165–1170. doi: 10.1016/0360-3016(90)90223-7. [DOI] [PubMed] [Google Scholar]
  2. Brown A. P., Fixsen J. A., Plowman P. N. Local control of Ewing's sarcoma: an analysis of 67 patients. Br J Radiol. 1987 Mar;60(711):261–268. doi: 10.1259/0007-1285-60-711-261. [DOI] [PubMed] [Google Scholar]
  3. Burgert E. O., Jr, Nesbit M. E., Garnsey L. A., Gehan E. A., Herrmann J., Vietti T. J., Cangir A., Tefft M., Evans R., Thomas P. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990 Sep;8(9):1514–1524. doi: 10.1200/JCO.1990.8.9.1514. [DOI] [PubMed] [Google Scholar]
  4. Chabora B. M., Rosen G., Cham W., D'Angio G. J., Tefft M. Radiotherapy of Ewing's sarcoma. Local control with and without intensive chemotherapy. Radiology. 1976 Sep;120(3):667–671. doi: 10.1148/120.3.667. [DOI] [PubMed] [Google Scholar]
  5. Daugaard S., Sunde L. M., Kamby C., Schiødt T., Jensen O. M. Ewing's sarcoma. A retrospective study of prognostic factors and treatment results. Acta Oncol. 1987;26(4):281–287. doi: 10.3109/02841868709089976. [DOI] [PubMed] [Google Scholar]
  6. Dunst J., Jürgens H., Sauer R., Pape H., Paulussen M., Winkelmann W., Rübe C. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):919–930. doi: 10.1016/0360-3016(95)00016-r. [DOI] [PubMed] [Google Scholar]
  7. Dunst J., Sauer R., Burgers J. M., Hawliczek R., Kürten R., Winkelmann W., Salzer-Kuntschik M., Müschenich M., Jürgens H. Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer. 1991 Jun 1;67(11):2818–2825. doi: 10.1002/1097-0142(19910601)67:11<2818::aid-cncr2820671118>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  8. Ellis F. Dose, time and fractionation: a clinical hypothesis. Clin Radiol. 1969 Jan;20(1):1–7. doi: 10.1016/s0009-9260(69)80043-7. [DOI] [PubMed] [Google Scholar]
  9. Glaubiger D. L., Makuch R. W., Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. Natl Cancer Inst Monogr. 1981 Apr;(56):285–288. [PubMed] [Google Scholar]
  10. Hendry J. H., Roberts S. A. The sensitivity of human tissues to changes in dose fractionation: deductions from the RCR survey among UK radiotherapists. Clin Oncol (R Coll Radiol) 1991 Jan;3(1):22–27. doi: 10.1016/s0936-6555(05)81036-2. [DOI] [PubMed] [Google Scholar]
  11. Kinsella T. J., Miser J. S., Waller B., Venzon D., Glatstein E., Weaver-McClure L., Horowitz M. E. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):389–395. doi: 10.1016/0360-3016(91)90047-8. [DOI] [PubMed] [Google Scholar]
  12. Mameghan H., Fisher R. J., O'Gorman-Hughes D., Bates E. H., Huckstep R. L., Mameghan J. Ewing's sarcoma: long-term follow-up in 49 patients treated from 1967 to 1989. Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):431–438. doi: 10.1016/0360-3016(93)90064-3. [DOI] [PubMed] [Google Scholar]
  13. Nesbit M. E., Jr, Gehan E. A., Burgert E. O., Jr, Vietti T. J., Cangir A., Tefft M., Evans R., Thomas P., Askin F. B., Kissane J. M. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990 Oct;8(10):1664–1674. doi: 10.1200/JCO.1990.8.10.1664. [DOI] [PubMed] [Google Scholar]
  14. Perez C. A., Tefft M., Nesbit M., Burgert E. O., Jr, Vietti T., Kissane J., Pritchard D. J., Gehan E. A. The role of radiation therapy in the management of non-metastatic Ewing's sarcoma of bone. Report of the Intergroup Ewing's Sarcoma Study. Int J Radiat Oncol Biol Phys. 1981 Feb;7(2):141–149. doi: 10.1016/0360-3016(81)90429-6. [DOI] [PubMed] [Google Scholar]
  15. Razek A., Perez C. A., Tefft M., Nesbit M., Vietti T., Burgert E. O., Jr, Kissane J., Pritchard D. J., Gehan E. A. Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma. Cancer. 1980 Aug 1;46(3):516–521. doi: 10.1002/1097-0142(19800801)46:3<516::aid-cncr2820460316>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  16. Smith L. M., Cox R. S., Donaldson S. S. Second cancers in long-term survivors of Ewing's sarcoma. Clin Orthop Relat Res. 1992 Jan;(274):275–281. [PubMed] [Google Scholar]
  17. Tefft M., Lattin P. B., Jereb B., Cham W., Ghavimi G., Rosen G., Exelby P., Marcove R., Murphy M. L., D'Angio G. J. Acute and late effects on normal tissues following combined chemo- and radiotherapy for childhood rhabdomyosarcoma and Ewing's sarcoma. Cancer. 1976 Feb;37(2 Suppl):1201–1217. doi: 10.1002/1097-0142(197602)37:2+<1201::aid-cncr2820370831>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES